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ABSTRACT
The aim of the present study was to develop and validate a 
High-Performance Liquid Chromatography (HPLC) method 
for the determination of lisinopril and gliclazide. The method 
was developed on Zorbax C8 analytical column (4.6x250 mm; 
5µm) by isocratic elution with a flow rate of 1.0 mL/min and 
injection volume of 25 µl. The mobile phase composition was 
methanol:water (65:35 v/v, pH adjusted to 3.0 triethylamine-
orthophosphoric acid buffer) and the retention time was 
found to be 2.883 and 7.456 min for lisinopril and gliclazide, 
respectively. The developed method was found to be linear in 
the concentration range of 5-20 µg/mL for lisinopril and 15-60 
µg/mL for gliclazide. The method was validated for linearity, 
accuracy, precision, LOD and LOQ. This developed procedure 
was succesfully applied conveniently for the analysis of lisinopril 
and gliclazide in pharmaceutical preparations.
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Development and validation of a reversed-phase HPLC method for the 
determination of lisinopril and gliclazide in pharmaceuticals
Introduction
Diabetes raises the risk of heart disease and other health 
issues. Having diabetes and hypertension together raises the 
risk of cardiovascular problems even more. Patients with 
diabetes should reach a target blood pressure of less than 
130/80 mm Hg [1-3].
Diabetes and hypertension are major risk factors for 
cardiovascular events, and share common pathways such 
as inflammation, oxidative stress and obesity [4]. For both 
of these diseases, genetic and lifestyle factors play central 
roles. It is important to control blood pressure for managing 
diabetes and many people will require three or more drugs to 
reach the recommended target.
Gliclazide (GLZ) is classified as a sulfonylurea and acts as 
an oral hypoglycemic agent used in the treatment of type-II 
diabetes mellitus [5-7]. It binds to pancreatic sulphonylurea 
receptors (SURs) on the surface of β-cells, by increasing the 
secretion of insulin. It also possesses antiplatelet properties 
with the free radical scavenger activity, by that means 
prohibiting vascular complications [8, 9].
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Lisinopril (LSP) is an angiotensin-converting enzyme (ACE) 
inhibitor and a lysine analogue of enalaprilat. Like all ACE 
inhibitors, lisinopril also displays antihypertensive activity. It 
is also used for myocardial infarction (MI), heart failure and 
diabetic nephropathy or retinopathy [10, 11].
Several methods have been previously reported for the 
determination of lisinopril [12-16] and gliclazide [17-20] by 
HPLC, UV spectrophotometry, LC-MS, etc. alone but there 
has been no single method reported for the determination 
of these drugs together. The aim of our present study was to 
develop and validate a new rapid and selective HPLC method 
for the simultaneous determination lisinopril and gliclazide 
in bulk and combined pharmaceutical dosage forms. The 
methods have been validated as per ICH requirements [21].
2. EXPERIMENTAL
2.1. Reagents and chemicals
Lisinopril dihydrate was used from the USP reference 
standard (83915-83-7) and gliclazide was kindly given by 
Deva Pharmaceuticals. Methanol was of HPLC reagent 
grade and purchased from Merck (Darmstadt, Germany). 
Triethylamine (TEA) and orthophosphoric acid (85%) were 
of analytical grade and procured from Fluka and Carlo-Erba, 
respectively. HPLC grade water was used to prepare the 
mobile phase.
2.2. Instrumentation
The HPLC system (Agilent 1100 series), consisted of G 
1311A Quat pump, G 1315A DAD detector, a manual 
injector, with Chem Station A-08,03 [847]-2000 software. 
Samples were injected with a Rheodyne injector system with 
a 25 µl sample loop. The detector was set at 215 nm and peak 
areas were automatically integrated by a computer using the 
Chem Station software program. Separation was carried 
out at an ambient temperature using a Zorbax C8 analytical 
column (4.6x250 mm, 5µm) by isocratic elution with a flow 
rate of 1.0 mL/min. The run time was set at 10 min with 
the system. All the calculations concerning the quantitative 
analysis were performed with external standardization by the 
measurement of peak areas.
SMILES codes were generated from the structures using the 
ACD/ChemSketch version 8.0 molecular editor (http://www.
acdlabs.com) and then log P values were calculated using the 
Molinspiration online property calculation toolkit (http://
www.molinspiration.com). The calculated log P values, 
chemical structures and names, molecular weights and 
formulas for the drug substances are given in Table 1.
Table 1. Structures and calculated physico-chemical properties of the APIs.
Structures and Chemical Name Formula & M.W. (g/mol) Log P*
Lisinopril dihydrate
(2S)-1-[(2S)-6-Amino-2-[[(1S)-1-carboxy-3-phenylpropyl]
amino]hexanoyl]pyrrolidine-2-carboxylic acid dihydrate
C21H35N3O7
441.518 -2.44
Gliclazide
N-(Hexahydrocyclopenta [c]pyrrol-2(1H)-ylcarbamoyl)-
4-methylbenzenesulfonamide 
C15H21N3O3S
323.410 1.45
*Log P values were calculated using Molinspiration software (http://www.molinspiration.com/ ).
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2.3. Stock and Standard Working Solutions
A standard solution containing lisinopril and gliclazide was 
prepared by weighing 10 mg and 30 mg respectively, and 
both the drugs dissolved in 100 mL mobile phase and the 
solution was sonicated for 10 min, the volume was made up 
to the mark with the mobile phase to obtain a stock solution 
of 100 µg/mL of LSP and 300 µg/mL of GLZ.
LSP and GLZ concentrations in the working solution chosen 
for the calibration curves were 5, 7.5, 10, 12.5, 15, 20 mg/mL 
and 15, 22.5, 30, 37.5, 45, 60 mg/mL, respectively. Samples 
(of low, medium and high concentration) at 8, 10 and 12 μg/
mL (for LSP) and 24, 30, 36 μg/mL (for GLZ) were prepared 
the same way as the calibration. These solutions were freshly 
prepared daily by making further dilutions of the stock 
solution in the mobile phase.
2.4. Mobile Phase
Preparation of 0.1% (v/v) triethylamine buffer (pH 3.0): 
Dissolve 1.0 mL of triethylamine in 900 mL of water then 
adjust the pH to 3.0 with diluted orthophosphoric acid, and 
dilute with water to 1 L, filter with Millicup-HV of 0.45-mm 
pore size.
2.5. Chromatographic Conditions
A HPLC analysis was performed by isocratic elution with a 
flow rate of 1.0 mL/min. The mobile phase composition was 
methanol:water (65:35 v/v, pH adjusted to 3.0). The pH of 
the mobile phase was adjusted to pH 3.0±0.05 with a diluted 
orthophosphoric acid solution. The mobile was stirred 
manually to mix and finally make the volume up to 1000 mL 
with water. Finally the mobile phase was filtered through a 0.45 
μm membrane filter and degassed for 10 min. The injection 
volumes for samples and standards were 25 μl and eluted at 
a flow rate of 1 mL/min. The retention time was found to be 
2.883 and 7.456 min for lisinopril and gliclazide, respectively 
(Figure 1A). Overlaid UV spectrum showed that both drugs 
showed good absorbance at 215 nm, hence the wavelength 
of 215 nm was selected for quantification of LSP and GLZ 
(Figure 1B). All solvents were filtered through a 0.45 µm 
millipore filter before use and degassed in an ultrasonic bath.
2.6. Calibration study
Mixed standard solutions containing lisinopril (5-20 µg/mL) 
and gliclazide (15-60 µg/mL) were prepared in the mobile 
phase. Triplicate 25 µl injections were made for each standard 
solution to see the reproducibility of the detector response 
at each concentration level. The peak area of each drug was 
plotted against the concentration to obtain the calibration 
graph. The five concentrations of each compound were 
subjected to a regression analysis to calculate the calibration 
equation and correlation coefficients.
Figure 1. (A) HPLC chromatogram acquired at 215 nm for 
LSP and GLZ reference standards; (B) UV spectra of LSP 
and GLZ using the mobile phase as blank.
3. RESULT AND DISCUSSION
3.1. Method Validation
The described method was partially validated with respect 
to system suitability, linearity, limit of detection (LOD) and 
quantitation (LOQ), precision, accuracy and specificity and 
selectivity.
3.1.1. Specificity
The specificity of an analytical method is its ability to 
accurately and specifically measure the analyte in the presence 
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of components that may be expected to be present in the 
sample matrix. To investigate the specificity of the analytical 
method, the blank was injected into the chromatographic 
system. There was no peak found at the retention time of the 
analyte in the placebo samples.
3.1.2. System suitability
The system suitability test is an integral part of 
chromatographic analysis. It is used to verify that the 
resolution and reproducibility of the system are adequate 
for the analysis. The results of theoretical plates (N), tailing 
factor (T), relative standard deviation (RSD) and retention 
time (Rt) of the method are shown in Table 2. System 
suitability requirements for drugs were a RSD of peak areas 
and retention times <1% (by making five replicate injections), 
a peak resolution (R) >2.0, theoretical plate numbers (N) 
≥2000 for each peak and USP tailing factors (T)<1.5. The 
result was satisfactory.
Table 2. System suitability results of the developed method
Compound Rt RSD R N T
LSP 2.883 0.36 2.57 4050 1.38
GLZ 7.456 0.35 19.91 11466 1.09
3.1.3. Linearity and range
Aliquots of standard stock solutions of lisinopril and 
gliclazide were taken in 10 mL volumetric flasks and diluted 
with the mobile phase to obtain final concentrations in the 
range of 5-20 μg/mL for lisinopril and 15-60 μg/mL for 
gliclazide. The solutions were injected using a 25 μl injection 
volume into the chromatographic system at a flow rate of 1.0 
mL/min and the effluents were monitored at 215 nm, and the 
calibration curve was obtained by plotting the peak area ratio 
versus the applied concentrations of the drugs. Triplicate 
injections were made for each concentration.
Following calibration experiments, concentration levels 
ranging from 5-20 μg/mL for LSP and 15-60 μg/mL for GLZ 
were found in linear correlation with the detector response. 
The correlation coefficients of regression equations were 
calculated as 0.9994 for LSP and GLZ and shown in Figure 2.
The limit of detection (LOD) is the smallest concentration 
that can be detected but not necessarily quantified as an exact 
value. The limit of quantification (LOQ) is the lowest amount 
of analyte in the sample that can be quantitatively determined 
with suitable precision and accuracy. LOD and LOQ values 
can be calculated according to the following equations:
LOD = 3.3 × σ / S
LOQ = 10 × σ / S
Where “S” is the standard deviation of response of the 
calibration curve and “S” is the slope of the curve. LODand 
LOQ values were found to be well within limits. The 
characterization of calibration plot values is shown in Table 3.
Figure 2. Calibration plots of GLZ and LSP
Table 3. Spectral and statistical data for determination of 
LSP and GLZ by proposed RP-HPLC method
LSP GLZ
Linearity range (µg/mL) 5-20 15-60
Slope* 32.901 31.438
Intercept* 525.67 1051.9
Correlation coefficient (r) 0.9994 0.9994
Limit of detection (µg/mL) 0.46 0.97
Limit of quantification (µg/mL) 1.42 2.95
*: Mean of three injections.
3.1.4. Accuracy
The accuracy was determined with recovery studies. In 
this validation study, the accuracy of the method has been 
investigated by calculating the recovery values obtained 
by analysing the solutions prepared with the lisinopril and 
gliclazide standard corresponding to 80%, 100% and 120% of 
the test concentration using the chromatographic parameters 
defined in the test procedure. The obtained results are 
presented in Table 4.
Şenkardeş et al.
Reversed-phase HPLC method for the determination of lisinopril and gliclazide Marmara Pharm J 21/2: 338-344, 2017342
Table 4. Results of accuracy study
Test solution Amount added 
(µg/ml)
Amount found
(µg/ml)
LSP Recovery 
(%)
Test solution Amount added
(µg/ml)
Amount found
(µg/ml)
GLZ
Recovery (%)
80% 8.0
8.007 100.09
80% 24.0
23.829 99.29
7.995 99.94 23.988 99.95
8.112 101.41 24.146 100.61
100% 10.0
9.933 99.33
100% 30.0
30.105 100.35
10.062 100.62 29.973 99.91
9.978 99.78 30.342 101.14
120% 12.0
11.938 99.49
120% 36.0
36.223 100.62
11.957 99.64 36.101 100.28
11.996 99.97 36.223 100.62
Mean
SD
RSD (%)
100.03 Mean
SD
RSD (%)
100.31
0.64 0.54
0.64 0.54
Table 6. Precision study parameter
Lisinopril Gliclazide
Results of the intraday precision
Conc.
(mg/mL)
Peak area 
(±SD) (n=5)
RSD% Conc.
(mg/mL)
Peak area 
(±SD) (n=5)
RSD%
10 915.8±7.70 0.84 30 2104.74±20.00 0.95
Results of the interday precision
10 896.3±6.70 0.75 30 2017.84±14.60 0.72
3.2. Application of the method in dosage forms
The combined dosage formulation of lisinopril and gliclazide 
was not available on the local market, therefore the laboratory 
sample mixture was prepared using Rilace® and Diamicron® 
tablets. Ten equivalently powdered tablets were mixed at a 
ratio of 10 mg lisinopril: 30 mg gliclazide. A quantity of this 
synthetic powder mixture equivalent to 40 mg was taken 
up in a 100 mL volumetric flask, and the mobile phase was 
added up to the mark. The solution was sonicated for 15 min. 
This solution was further diluted to obtain a concentration 
of 10 μg/mL LSP and 30 μg/mL GLZ. The assay results were 
compiled, found satisfactory and showed that there is a no 
interference of tablet matrix with the drug and the results are 
summarized in Table 7. The results show that this method 
can be easily applied for the estimation of LSP and GLZ in 
bulk drug and in the tablet mixture.
3.1.5. Precision
The precision of a method is usually expressed as the 
standard deviation or relative standard deviation (RSD) of 
series of measurement.
The system precision or repeatability of the method was 
checked by repeatedly injecting five sample solutions of 
LSP (10 μg/mL) and GLZ (30 μg/mL) under the same 
chromatographic condition and measurements of peak area, 
retention time and tailing factor. The percentage relative 
standard deviation (RSD) was found to be <2.0% (Table 5).
Table 5. System precision test results
Test solution LSP Area GLZ Area
1 900.6 2056.8
2 906.5 2046.5
3 915.1 2032.9
4 900.9 2068.6
5 907.3 2035.1
Mean 906.5 2047.9
SD 5.91 14.99
RSD (%) 0.65 0.73
The intraday and interday precision of the proposed method 
was determined by analysing the corresponding responses 
five times on the same and different days over a period of 
one week for 100% concentrations of sample solutions of the 
drugs. The results were reported in terms of relative standard 
deviation (RSD) (Table 6).
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Table 7. Determination of LSP and GLZ in synthetic tablet blends.
Tablet mixture Drug Amount added (mg) in 
tablet mixture (1:3)
Amount found (mg) (n=3) 
±SD
% Amount obtained ±SD
Lisinopril+Gliclazide
Lisinopril 10 9.97±0.18 99.82±0.70
Gliclazide 30 30.22±0.25 100.34±0.39
without any interference from the excipients in laboratories 
and in the pharmaceutical industry.
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4. CONCLUSION
The developed method is suitable for the identification 
and quantification of the binary combination of lisinopril 
and gliclazide. The mobile phase is simple and economical 
to prepare. Validation studies revealed that, the proposed 
method was found to be rapid, accurate, precise, specific, 
robust and economical. Hence, the proposed method can be 
used for routine analyses of both drugs in the process control 
of the bulk drug and (potential) combined dosage forms 
Farmasötik ürünlerde lisinopril ve gliklazid tayini için 
ters faz-yüksek basınçlı sıvı kromatografisi yönteminin 
geliştirilmesi ve validasyonu
ÖZET
Mevcut çalışmanın amacı, lisinopril ve gliklazid etken maddeleri 
için yüksek performanslı sıvı kromatografisi kullanılarak 
bir analitik yöntemin geliştirilmesi ve validasyonunu 
kapsamaktadır. İzokratik ayırım ile sağlanan bu yöntem, 25 
mikrolitre enjeksiyon hacmi ve 1.0 mL/dk’ya akış hızı ile 
Zorbax C8 analitik kolon (4.6x250 mm; 5µm) kullanılarak 
geliştirilmiştir. Hareketli faz bileşimi metanol:su içermekte olup 
(65:35 v/v, pH=3’e trietilamin-ortofosfat tamponu ile ayarlı) 
lisinopril ve gliklazid için alıkonma zamanı sırasıyla 2.883 ve 
7.456 dk. olarak bulunmuştur. Geliştirilen bu yöntem lisinopril 
için 5-20 µg/mL konsantrasyon aralığında, gliklazid için ise 
15-60 µg/mL konsantrasyon aralığında doğrusaldır. Yöntem 
doğrusallık, kesinlik, doğruluk ve LOD-LOQ validasyon 
parametreleri açısından valide edilmiştir. Geliştirilen bu 
prosedür lisinopril ve gliklazidin farmasötik preparatlarının 
analizlerinde güvenli bir şekilde uygulanabilir.
Anahtar Kelimeler: Kombine dozaj formu, gliklazid, lisinopril, 
ters faz-HPLC, yöntem geliştirme
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